Alzheimer’s Disease

HittPack™

A search of the latest news and medical research findings

October 4, 2011
Contents

I. Disease and Treatment Information in Alzheimer’s Disease .......................................................... 2

II. Recent News Articles in Alzheimer’s Disease ............................................................................... 2
    Medscape Medical News (free password required) ........................................................................ 2
    MedpageToday .............................................................................................................................. 4
    Reuters .......................................................................................................................................... 7

III. Press Releases in Alzheimer’s Disease ......................................................................................... 10
    Eurekalert.org .............................................................................................................................. 10
    Newswise.com .............................................................................................................................. 16
    Google.com .................................................................................................................................. 23

IV. US Food and Drug Administration Info on Alzheimer’s Disease ................................................. 25
    Drugs@FDA Database .................................................................................................................. 25
    2011 Advisory Committee Meetings .............................................................................................. 27

V. Guidelines in Alzheimer’s Disease .............................................................................................. 28
    National Guidelines Clearinghouse--Guidelines.gov ................................................................. 28
    National Institute on Aging/Alzheimer’s Association ................................................................. 30
    American Psychiatric Association ............................................................................................... 30

VI. Conferences and Medical Associations for Alzheimer’s Disease ................................................. 30
    Conferences ................................................................................................................................. 30
    Medical Associations .................................................................................................................. 31

VII. Key Opinion Leaders in Alzheimer’s Disease ............................................................................ 31

VIII. Clinical Trials in Progress in Alzheimer’s Disease ................................................................. 32

IX. PubMed Search in Alzheimer’s Disease ...................................................................................... 42
    Randomized Controlled Trials ..................................................................................................... 42
    Reviews ......................................................................................................................................... 45
    Editorials ....................................................................................................................................... 48
I. Disease and Treatment Information in Alzheimer’s Disease

- PubMed Health – Alzheimer’s Disease  
- National Institute on Aging - Alzheimer’s Disease Fact Sheet  
  http://www.nia.nih.gov/Alzheimers/Publications/adfact.htm
- MedlinePlus - Alzheimer’s Disease  
- Mayo Clinic – Alzheimer’s Disease  
  http://www.mayoclinic.com/health/alzheimers-disease/DS00161

II. Recent News Articles in Alzheimer’s Disease

Medscape Medical News (free password required)  
http://www.medscape.com/; search term = Alzheimer’s Disease; first 20 results sorted by date

- Reassuring Findings on Anticholinergics in Dementia Patients  
  New research suggests that medications with mild anticholinergic effects don’t cause further cognitive decline in patients with Alzheimer’s disease.  
  News, Medscape Medical News, October 2011

- Levodopa Does Not Accelerate Parkinson’s Pathology  
  ... does not support speculation that levodopa contributes to the neurodegenerative process in Parkinson's disease, but some experts say more study is needed.  
  News, Medscape Medical News, October 2011

- Primary Care: You DO Need to Know About Genomics -- Here's Why  
  ... more about what we call multifactorial conditions," reminds Feero. Heart disease, diabetes, Alzheimer disease -- genomics is increasingly relevant to ...  
  Article, Medscape Business of Medicine, October 2011

- Neurochemical Dementia Diagnostics in Alzheimer’s Disease  
  ... process for patients with neurodegenerative disorders, such as Alzheimer's disease. Currently, two groups of biomarkers analyzed in the ...  
  Journal Article, Expert Rev Proteomics, September 2011

- Atrial Fibrillation and Risk of Dementia  
  ... fibrillation (AF) is associated with risk of incident dementia or Alzheimer's disease (AD), beyond its effect on stroke. Design: Prospective cohort ...  
  Journal Article, J Am Geriatr Soc, September 2011
▪ **Blood Pressure Changes Linked to Cerebral Leukoaraiosis** Results from the Atherosclerosis Risk in Communities study show that various aspects of BP play a role in the progression of white matter hyperintensity. News, Medscape Medical News, September 2011

▪ **Not All Memory Complaints Signal Trouble** Researchers find that the type and number of subjective memory complaints provides useful information to guide cognitive testing. News, Medscape Medical News, September 2011

▪ **Can You Tell if Your Patients Can’t Make Decisions?** ... had the highest prevalence of incapacity (68%), followed by adults with Alzheimer disease (54%) and residents of nursing homes (44%). The majority of ... Experts And Viewpoints, Medscape Family Medicine, September 2011

▪ **MR Spectroscopy: Is It a Clinical Contender?** ... such as the metabolic assessment of stroke, seizure disorders, Alzheimer disease, and even depression. Gathering these data takes relatively ... Article, Medscape Radiology, September 2011

▪ **Intensive Blood Glucose Lowering Has No Cognitive Benefit** ... often have other disorders, including high blood pressure, microvascular disease and macrovascular disease, all of which can contribute to cognitive ... News, Medscape Medical News, September 2011

▪ **Depression in Later Life a Harbinger of Dementia** ... have found that people who had early-life depression had a risk of Alzheimer disease in later life," lead author Ge Li, MD, PhD, from the University ... News, Medscape Medical News, September 2011

▪ **Off-Label Atypical Use: Few Benefits, Serious Adverse Effects** A new meta-analysis shows few benefits and significant adverse effects associated with the off-label use of atypical antipsychotics. News, Medscape Medical News, September 2011

▪ **Low Vitamin B12 Tied to Brain Atrophy, Cognitive Impairment** A new study highlights the importance of often-unmeasured vitamin B12 metabolites to brain health. News, Medscape Medical News, September 2011

▪ **Othello Syndrome—At the Interface of Neurology and Psychiatry** ... be associated with delusions in some degenerative disorders, such as Alzheimer disease (AD).[4] Othello syndrome is a psychotic disorder that often ... Journal Article, Nat Rev Neurol, September 2011

▪ **Novel Pathway, Potential Drug Target for FTD Identified** ... for frontotemporal dementia that could lead to a potential drug target for the disease, which is the second most common cause of presenile dementia. News, Medscape Medical News, September 2011

▪ **Role of Amyloid-β-metal Interactions in Alzheimer’s Disease** ... metals such as copper, zinc and iron play a part in the pathogenesis of Alzheimer’s disease. Could normalizing metal ion homeostasis be a viable ... Journal Article, Future Neurology, September 2011
• **China 'Stem Cell Therapies' Offer Heartbreak for Many** ... inquiries from patients asking about therapies in China and Brazil for diseases from Alzheimer's to spinal cord injuries. "What I'm talking about are ... News, Reuters Health Information, September 2011

• **Support Grows for Diabetes–Dementia Link** ... a significant risk factor for the development of dementia, especially Alzheimer's disease (AD), a new study suggests. Among more than 1000 Japanese ... News, Medscape Medical News, September 2011

• **World Alzheimer Report 2011 Encourages Earlier Diagnosis** ... evidence shows that it is possible to promote earlier diagnosis of Alzheimer's disease (AD), and that early therapeutic intervention can improve ... News, Medscape Medical News, September 2011

• **17β-Estradiol Improves Postmenopausal Memory Performance** ... healthy women between the ages of 49 and 68 years who were at risk for Alzheimer's disease (AD), those receiving hormone therapy containing ... News, Medscape Medical News, September 2011

**MedpageToday**

http://www.medpagetoday.com/; search term = Alzheimer's Disease; 18 most recent results

<table>
<thead>
<tr>
<th>Blood Test Predicts Course of Alzheimer's</th>
<th>Biomarkers Flunk Alzheimer's Test</th>
<th>Age and HF Linked to Memory Loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma levels of sphingolipid compounds can predict progression of Alzheimer's disease, a small, early, observational study showed.</td>
<td>Changes in cognitive function outperformed biomarkers for predicting conversion from mild impairment to Alzheimer disease, a retrospective review of medical records showed.</td>
<td>Older people with a reduced left ventricular ejection fraction have significant memory impairments, compared with their younger counterparts, researchers reported.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Most Off-Label Use of Antipsychotics Unsupported</th>
<th>Vessel Calcium Points to Brain Disease</th>
<th>PET Tracers May Help Predict Alzheimer's</th>
</tr>
</thead>
<tbody>
<tr>
<td>There's little evidence to support the use of atypical antipsychotic drugs for substance abuse,</td>
<td>Calcification in major blood vessels measured with CT scans</td>
<td>An investigational PET tracer</td>
</tr>
</tbody>
</table>
eating disorders, and most other off-label indications, according to a systematic literature review.

**Brain Takes Multiple Hits from Low B12 Levels**
9/26/2011

Low levels of vitamin B12 may contribute to cognitive problems for older adults in more than one way, according to a cross-sectional study.

**Diabetes Linked to Alzheimer's Risk**
9/20/2011

Dementia risk may rise when glucose gets out of control, particularly after meals, according to a longitudinal Japanese study.

**Coach Summitt to Stay in Game After Alzheimer Diagnosis**
8/24/2011

Pat Summitt, the most successful college basketball coach of all time, said she plans to continue leading her University of Tennessee women's team this season after receiving a diagnosis of early-onset Alzheimer's disease.

**New Nerve Cells Made from Skin**
8/4/2011

For the first time, human skin cells have been directly transformed into functional nerve cells, opening a way for cell replacement therapies for neurodegenerative conditions such as Alzheimer's disease, researchers reported.

**Lab Notes: HIV, the Consummate Escape Artist**
8/19/2011

Researchers have found yet another way in which HIV may elude the effects of antiretroviral drugs. Also in this week's Lab Notes, researchers have found clues to the true cause of an ancient female Pharaoh's demise.

**Lab Notes: Decaf Coffee, Sugar, and Pruning Shears**
7/22/2011

This week's installment of Lab Notes features the role of decaf coffee in Alzheimer's disease,
FDA Blocks Sale of Supplements for Parkinson’s and Alzheimer’s Disease
9/16/2011
WASHINGTON -- The FDA filed a permanent injunction against two Minnesota companies that distributed amino acid products marketed as treatments for Parkinson’s disease, Alzheimer’s disease, and a number of other neurological disorders.

Insulin Nasal Spray May Slow Alzheimer’s Disease
9/12/2011
Intranasal insulin therapy may have beneficial effects on cognition and function among patients with Alzheimer’s disease, a pilot study suggested.

Dementia Differs in the Oldest Old
8/11/2011
The oldest patients with Alzheimer’s disease appear to have less profound changes in cognitive function and in cortical structure than patients who develop the disease at a younger age, a retrospective case-control study found.

Sleep Apnea Tied to Worse Cognition
8/9/2011
Older women with sleep-disordered breathing are more likely to develop cognitive impairment than those who don’t have sleep problems, researchers found.

ICAD: Tesamorelin Boosts Cognition in Elderly
7/21/2011
PARIS -- A drug that increases growth hormone release improved several measures of cognitive function in cognitively normal and mildly impaired older individuals, a researcher said here.

Vascular Dementia Rate Edges Alzheimer's Disease
7/21/2011
The rate of dementia in those older than 65 in developed countries can be as high as 10%, according to a scientific statement from the American Heart Association/American Stroke Association.
Addex to Present Progress on Multiple Allosteric Modulator ...

... Thursday, October 6, 4.30 - 4.55 pm Selective mGluR2 negative allosteric modulators for the treatment of cognitive deficits associated with Alzheimer's disease. ...

Mon Oct 3, 2011 12:01pm EDT

Targacept depression drug: high risk, high reward

... broader pipeline of experimental products, which include treatments for schizophrenia, attention deficit hyperactivity disorder and Alzheimer's disease. ...

Mon Oct 3, 2011 4:32pm EDT

GLAAD Study: Fewer Characters With Disabilities on Network TV This ...

... on “House,” Dr. Gregory House, uses a cane, Artie Abrams on “Glee” uses a wheelchair, and Maw Maw on “Raising Hope” has Alzheimer's disease. ...

Wed Sep 28, 2011 9:49am EDT

GLAAD study notes few characters with disabilities on TV

... title character on "House," Dr. Gregory House, uses a cane, Artie Abrams on "Glee" uses a wheelchair, and Maw Maw on "Raising Hope" has Alzheimer's disease. ...

Wed Sep 28, 2011 4:03pm EDT

Biotie to Acquire Newron Creating a Leading European ...

... Merck Serono has exclusive worldwide rights to develop, manufacture and commercialize safinamide in Parkinson’s disease, Alzheimer's disease and other ...

Tue Sep 27, 2011 1:01am EDT

Gene helps explain a third of inherited ALS cases

... FTD is the second most common form of early onset dementia after Alzheimer's. As the disease kills brain cells in the frontal lobe, it destroys people's ...

Wed Sep 21, 2011 1:09pm EDT
Factbox: How advanced is stem cell research?

... that claim to cure all kinds of diseases like diabetes, multiple sclerosis, arthritis, vision problems, Alzheimer's and Parkinson's disease and spinal cord ...

Wed Sep 21, 2011 3:44am EDT

More questions arise about "life-extending" proteins

... role in treating the diseases of aging, such as diabetes and Alzheimer's, so it's ... the understanding of the role of sirtuins in human health and disease nor in ...

Wed Sep 21, 2011 2:25pm EDT

Former Senator Charles Percy, a liberal Republican, dies

... She is the wife of US Senator John D. Rockefeller of West Virginia, and disclosed in early 2009 that her father was suffering from Alzheimer's disease. ...

Sat Sep 17, 2011 1:50pm EDT

Bayer to reshuffle diagnostics business

... Injection of flurbetaben highlights proteins which are associated with Alzheimer's disease in patients' brains under a positron emission tomography (PET) scan. ...

Fri Sep 16, 2011 7:49am EDT

Most cases of dementia are not diagnosed: report

... of life for millions of people," said Dr. Daisy Acosta, chairman of Alzheimer's Disease International, a patient advocacy group that sponsored the study. ...

Tue Sep 13, 2011 10:14am EDT

Insulin spray aided memory in Alzheimer's study

... "Our results suggest that the administration of intranasal insulin may have a therapeutic benefit for adults with aMCI or Alzheimer's disease," Suzanne Craft ...

Mon Sep 12, 2011 4:05pm EDT

German stocks - Factors to watch on September 6

... EVOTEC. Indicated 13.6 percent higher. Evotec said it and Roche have agreed to develop a compound that could slow the progression of Alzheimer's disease. ...
Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease.

Nearly 40 pct of Europeans suffer mental illness

Nearly 40 percent of Europeans suffer mental illness

Addex Regains Rights to Parkinson's Drug Candidates from Merck

Campbell's "Ghost" moving, if not always satisfying, farewell

Doctors join boxing debate as "vigorous" opponents

Review: Glen Campbell's 'Ghost' a Moving -- But Not Entirely...
... play the victim in the inevitably imbalanced relationship between disease victim and caretaker. No one would wish an extra memory loss on an Alzheimer's patient ...

Mon Aug 29, 2011 4:48pm EDT

III. Press Releases in Alzheimer's Disease

Eurekalert.org

www.eurekalert.org; search term = Alzheimer's Disease; first 20 results.

Study reveals link between high cholesterol and Alzheimer's disease

... link between high cholesterol and Alzheimer's disease ... a higher risk of developing Alzheimer's disease, according to a study published ... to brain plaques associated with Alzheimer's disease," said study author Kensuke Sasaki ...


Study finds enzyme disrupting nerve cell communication in Alzheimer's disease

... disrupting nerve cell communication in Alzheimer's disease ... elevated in the brains of Alzheimer's disease patients, where it triggers damage ... JOLLA, Calif., August 15, 2011 – Alzheimer's disease is characterized by abnormal proteins ...


Natural chemical found in grapes may protect against Alzheimer's disease

... in grapes may protect against Alzheimer's disease ... or delay the progression of Alzheimer's disease. The research, led by Giulio ... similar to those found in Alzheimer's disease. They
found that the brain...


**New biomarker may help with early diagnosis of Alzheimer's disease**

... help with early diagnosis of Alzheimer's disease will go on to develop Alzheimer's disease, according to a new study... those who did not develop Alzheimer's disease. Those who developed Alzheimer's disease had an average of 1...


**Arrowing in on Alzheimer's disease**

... Arrowing in on Alzheimer's disease known to be associated with Alzheimer's disease has increased from four to ... cluster which is associated with Alzheimer's disease...


**Stress may increase risk for Alzheimer's disease**

... Stress may increase risk for Alzheimer's disease that are also seen in Alzheimer's disease. Scientists from the Max Planck... are a typical feature of Alzheimer's disease: the excessive alteration of the...


**Clinical trials for new Alzheimer's disease treatment to be**

Hitt Medical Writing, LLC © 2011 www.hittmedicalwriting.com
<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
<th>Link</th>
</tr>
</thead>
</table>
Alzheimer's disease risk... Available drugs only marginally affect disease severity and progression, making Alzheimer's disease effectively untreatable.

Alzheimer's disease invariably progresses to complete incapacitation...


Indications of Alzheimer's disease may be evident decades before first signs of cognitive...

... Indications of Alzheimer's disease may be evident decades before... have found that patients with Alzheimer's disease have lower glucose utilization in... to the first symptoms of Alzheimer's disease. This new finding could lead...


More evidence that Alzheimer's disease may be inherited from your mother

... More evidence that Alzheimer's disease may be inherited from your... one of your parents has Alzheimer's disease, the chances of inheriting it... have first-degree relatives with Alzheimer's disease are four to 10 times...


Brain's 'autopilot' provides insight into early development of Alzheimer's disease

... insight into early development of Alzheimer's disease... making an early diagnosis of Alzheimer's disease, according to researchers at Duke... and imaging studies conducted in
Alzheimer's disease have focused on the anatomy ...


High levels of 'good' cholesterol may be associated with lower risk of Alzheimer's disease

... associated with lower risk of Alzheimer's disease ... with a reduced risk for Alzheimer's disease in older adults, according to ... and triglycerides] and late-onset Alzheimer's disease are highly frequent in western ...


Study suggests earliest brain changes associated with the genetic risk of Alzheimer's ...

... with the genetic risk of Alzheimer's disease ... with the risk of developing Alzheimer's disease? A scientific report published in ... common genetic risk factor for Alzheimer's disease—before the protein changes or ...


Diabetes gene linked to degeneration of enzyme involved in Alzheimer's disease onset and ...

... degeneration of enzyme involved in Alzheimer's disease onset and progression ... normal levels in people with Alzheimer's disease. The research, led by Giulio ... the onset and progression of Alzheimer's disease. Recent evidence indicates that healthy ...

Low testosterone linked to Alzheimer's disease

... Low testosterone linked to Alzheimer's disease ... older men at risk for Alzheimer's disease. The researchers ... associated with the onset of Alzheimer's disease, according to research by a ...


Researchers identify genetic marker of aggressive Alzheimer's disease

... identify genetic marker of aggressive Alzheimer's disease ... key proteins tend to characterize Alzheimer's disease in the brain. Amyloid makes ... An international team of Alzheimer's disease experts, led by Washington University ...


Protein-based biomarkers in blood serum could classify individuals with Alzheimer's disease

... serum could classify individuals with Alzheimer's disease ... to accurately classify patients with Alzheimer's disease, according to a report in ... of 197 patients diagnosed with Alzheimer's disease and 203 controls without Alzheimer's disease. Statistical analyses were used to ...


3 biomarkers in spinal fluid appear helpful to classify patients with Alzheimer's disease

... helpful to classify patients with Alzheimer's disease ... who
had been diagnosed with Alzheimer's disease but also was found in ... The initiation of the Alzheimer's disease pathogenic process is typically unobserved ...

research, but advances in this area have become ensnared in litigation again and again. Esther Landhuis and Gabrielle Strobel investigated: Buckle your seatbelt for a ride through the maze that is U.S. patent law, and sit in wonder at the multitude of obstacles that stand in the way of finding treatments for loved ones. view

Towards Clinical Trials in Very Early Alzheimer Disease - Before Symptoms Appear
Alzheimer Research Forum Foundation
2010-06-14
On the 9 June 2010, 119 participants from industry, academia, and related stakeholder communities in the U.S. and Europe joined Alzforum for a Webinar with Alzheimer's Disease Cooperative Study (ADCS) director Paul Aisen, who explained what kinds of project ideas the ADCS leaders welcome from the worldwide Alzheimer Disease research community as they prepare for a new round of federal ADCS funding next year. The ADCS runs trials with public-private collaborations, and has developed a clinical trial infrastructure and a tool kit well suited to push drug trials into the pre-symptomatic phase of the disease. view

Deep-Brain Stimulation: Calms PD Shakes—What About the Mind?
Alzheimer Research Forum Foundation
2010-05-27
A surgical treatment that stimulates distressed neural networks through electrodes threaded directly into a person's brain has quietly made a difference in the lives of tens of thousands of people with Parkinson disease, essential tremor, and dystonia over the course of the past decade. What about the mind? Could DBS eventually help other brain diseases such as Alzheimer's? Alzforum reporter Amber Dance investigates in a new four-part series. view

Genetic Mutation Associated with Famous Alzheimer Patient May Have Been Identified
Alzheimer Research Forum Foundation
2010-05-25
Writing the latest pages of an anthropological mystery, scientists propose in this month’s Archives of Neurology that it is highly possible that Auguste Deter, the first identified Alzheimer disease patient, carried the N141I presenilin-2 mutation—the same one as in present-day U.S. families descended from German emigrants who settled near the river Volga in Russia. view

Biomarkers Weigh In at Mild Cognitive Impairment Meeting
Alzheimer Research Forum Foundation
2010-04-20

Forget sun, sand, and surf—it was biomarker pools and a sea change in neurocognitive testing that rejuvenated attendees at the 8th Annual Symposium on Early Alzheimer’s, held 12-13 March 2010, in Miami Beach, Florida. Our intrepid reporter Pat McCaffrey brings you a full meeting summary, complete with a slide deck that covers the majority of presentations. view

Has the Clock Struck 12 for Dimebon?

Alzheimer Research Forum Foundation

2010-03-08

The Alzheimer Research Forum, an authoritative news source for neurodegenerative disease research, has reported extensively on the story of Dimebon, which was just reported to have failed in a clinical trial. view

Alzforum’s 5-Part Series on Alzheimer’s Prevention Initiative

Alzheimer Research Forum Foundation

2010-03-05

The field is abuzz with the word “prevention,” but how to pull off this vaunted goal? It’s been held back by a strange Catch-22 of cost, time, and biomarker validation. That might change with a bold initiative led by Eric Reiman, Pierre Tariot, and others at the Banner Alzheimer’s Institute. Read Gabrielle Strobel’s five-part series. view

Vision of Shared Prevention Trials Lures Pharma to Table

Alzheimer Research Forum Foundation

2010-02-26

The field of Alzheimer disease research is abuzz with the word “prevention,” but how to pull off this vaunted goal? It’s been held back by a strange Catch-22 of cost, time, and biomarker validation. That might change with a bold initiative led by Eric Reiman, Pierre Tariot, and others at the Banner Alzheimer’s Institute. Read Gabrielle Strobel’s 5-part series. view

Top Alzheimer Research Trends of 2009

Alzheimer Research Forum Foundation

2010-02-09
Known for their cutting-edge coverage of Alzheimer research news, the editors of Alzforum have compiled a list of the most important trends from the past year. view

Neurodegenerative Disease Research Highlights from Annual Society for Neuroscience Meeting

Alzheimer Research Forum Foundation

2009-11-18

The Web's leading source for research news on Alzheimer’s and related neurodegenerative diseases reports from the world's largest annual gathering of neuroscientists. view

Familial Alzheimer Disease Network Enrolling, Making First Move Toward Clinical Trials

Alzheimer Research Forum Foundation

2009-11-05

Alzheimer's researchers from around the world spent a day at Washington University in St. Louis with caregivers and patients of families with dominantly inherited Alzheimer disease. They exchanged not only scientific news but also harrowing perspectives about a form of AD that strikes in generation after generation. view

Sleep Deprivation Taxes Neurons, Racks Up Brain Amyloid-beta?

Alzheimer Research Forum Foundation

2009-09-28

While the occasional all-nighter to cram for exams or finish a grant proposal may seem like no big deal, losing sleep night after night could take its toll on brain health in later life, two new studies suggest. Read the full report on Alzforum. view

New Genetic Discoveries at International Alzheimer Conference

Alzheimer Research Forum Foundation

2009-08-14

The Alzheimer Research Forum provides a definitive round-up of the latest research findings presented at the recent International Conference on Alzheimer's Disease. view

The Latest Research on Mild-Cognitive Impairment

Alzheimer Research Forum Foundation

2009-06-11
In the past decade, the concept of mild cognitive impairment (MCI) has provided a way of identifying people at elevated risk of developing Alzheimer disease. MCI has been difficult to put in practice at times, but all the same has opened a window of opportunity for early detection, intervention, and some clinical trials. At the 7th Annual MCI Symposium, held 27-28 March in downtown Miami, Florida, 24 speakers covered the waterfront on this topic.

Mixed Neurodegenerative Disorders are Emerging from the Shadows

Alzheimer Research Forum Foundation

2009-05-29

Many cases of age-related neurodegenerative disease fall into the gray zone between big, defined diseases such as Alzheimer or Parkinson disease. They are often misdiagnosed, which is a problem because mixed disease is not only common, but also quite different in its course from pathologically 'pure' disease. But there's also excitement and opportunity.

Latest Updates from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

Alzheimer Research Forum Foundation

2009-05-22

The Alzforum reports on the analyses of one-year data (preliminary and mostly unpublished) from the $64-million Alzheimer's Disease Neuroimaging Initiative (ADNI). Scientists reported, and debated, these much-anticipated findings at recent ADNI internal meeting and a few days later in an ADNI session at the 61st Annual Meeting of the American Academy of Neurology (AAN), both in Seattle.

Latest Findings on Imaging of Human Brain Amyloid

Alzheimer Research Forum Foundation

2009-05-13

The web's foremost website on Alzheimer disease reports on the highlights from the 3rd annual Human Amyloid Imaging (HAI) conference held recently in Seattle, WA. Amyloid beta, a peptide that builds up abnormally in the brains of Alzheimer patients, can be studied by brain imaging. This landmark advance promises to yield new insights into how brain changes with aging and Alzheimer disease.

Studies Reveal New Hope, Old Problems With AD Biomarkers

Alzheimer Research Forum Foundation

2009-04-26
Three recent papers highlight new promise, and expose nagging pitfalls, of one of the Alzheimer field's most widely used surrogate measures of disease progression. Developing validated biomarkers is critical for developing better diagnostics and treatments. view

Latest Updates from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

Alzheimer Research Forum Foundation

2009-05-22

The Alzforum reports on the analyses of one-year data (preliminary and mostly unpublished) from the $64-million Alzheimer's Disease Neuroimaging Initiative (ADNI). Scientists reported, and debated, these much-anticipated findings at recent ADNI internal meeting and a few days later in an ADNI session at the 61st Annual Meeting of the American Academy of Neurology (AAN), both in Seattle. view

Latest Findings on Imaging of Human Brain Amyloid

Alzheimer Research Forum Foundation

2009-05-13

The web's foremost website on Alzheimer disease reports on the highlights from the 3rd annual Human Amyloid Imaging (HAI) conference held recently in Seattle, WA. Amyloid beta, a peptide that builds up abnormally in the brains of Alzheimer patients, can be studied by brain imaging. This landmark advance promises to yield new insights into how brain changes with aging and Alzheimer disease. view

Studies Reveal New Hope, Old Problems With AD Biomarkers

Alzheimer Research Forum Foundation

2009-04-26

Three recent papers highlight new promise, and expose nagging pitfalls, of one of the Alzheimer field's most widely used surrogate measures of disease progression. Developing validated biomarkers is critical for developing better diagnostics and treatments. view

Remembering a Forgotten Co-discoverer of Alzheimer Disease

Alzheimer Research Forum Foundation

2009-04-09

Alzheimer disease researchers everywhere are familiar with the founding story of their field, concerning the German doctor, Alois Alzheimer, who reported on abnormal pathology in the brain of
a woman who suffered from dementia. But scientists digging through historical archives in Prague have brought to light the existence of another investigator who made arguably even greater contributions to describing the disease, but whose contributions were tragically forgotten. view

Pioneering Biomedical Web Community Poised for Leap to Web 3.0

Alzheimer Research Forum Foundation

2009-03-13

The Alzheimer Research Forum (www.alzforum.org), a dynamic, biomedical Web community that is heavily used by Alzheimer researchers around the world, is preparing to migrate to a new platform that will enable it to more fully exploit social networking ("Web 2.0") and the Semantic Web ("Web 3.0"). view

"Smart Drugs" for Aging Minds: Doable? Ethical?

Alzheimer Research Forum Foundation

2009-02-18

Can we and should we develop drugs to stem memory loss that accompanies normal aging? The Alzheimer Research Forum invite a legal ethicist, FDA representative, several clinician-researchers, and other thought leaders to debate this topic in a Live Web Discussion on February 26, 2009, 12-1pm (U.S. EST). view

The Silver Lining in a Heartbreaking Disease

Alzheimer Research Forum Foundation

2008-11-13

Individuals who have Early-onset Familial Alzheimer Disease (eFAD) can in theory be studied and targeted for preventive treatments, but because they are few and far between, researchers doubted such studies were feasible. Now, the Dominantly Inherited Alzheimer Network (DIAN,) is set to tackle this challenge. The web's leading resource on AD research explains the premise and promise of DIAN. view

A Look Inside a "Big Science" Initiative for Alzheimer Disease

Alzheimer Research Forum Foundation

2008-10-17

The Alzheimer Research Forum releases a six-part series on the Alzheimer's Disease Neuroimaging Initiative, a massive effort to identify biomarkers to predict individuals' risk of AD. The Alzforum
reports on the first, much-awaited data from the study, and takes readers behind the scenes for a look at the challenges that had to be overcome. view

New Web Site Provides a Handle on Alzheimer Risk Factors

Alzheimer Research Forum Foundation

2008-10-07

What lifestyle factors are associated with the risk of getting Alzheimer disease? For an anxious public scanning the headlines, the answer seems to depend on the latest study. One week readers may be exhorted to eat more fresh fruits and vegetables, while the next week they are warned about metabolic disorder. But what does the research really show over dozens of studies comprising tens of thousands of people? view

National Policy Discussion on Diagnosing Early-Stage Alzheimer's

Alzheimer Research Forum Foundation

2008-07-03

The Alzheimer Research Forum, the Web's foremost community of AD researchers, has assembled a panel of thought leaders to address the challenges and solutions to early-diagnosis of AD in a "virtual town hall meeting." The event is scheduled for Wednesday, July 9, from 2:00-3:30 p.m. (U.S. East Coast Time) and will be conducted using Webinar technology and teleconferencing. view

Google.com

Search term = “Alzheimer's Disease press release”. First 10 results returned

1. IAD - Press Releases
   6-January-2010 - Cell Phone Exposure May Protect Against and Reverse Alzheimer's Disease. Contacts: Gary Arendash Florida Alzheimer's Disease Research ... 

2. IAD - Press Releases
   24-May-2010 - Alcohol Consumption May Protect Against Risk of Alzheimer's ... 

3. A sweet solution for Alzheimer's disease? (press release)
   www.naturalnews.com/019855.html
4. Stress significantly hastens progression of Alzheimer's disease ...
   www.naturalnews.com/020799.html
   Stress significantly hastens progression of Alzheimer's disease (press ... 

5. Calorie Restriction May Prevent Alzheimer's Disease (press release)
   www.naturalnews.com/019905.html
   Aug 8, 2006 – Calorie Restriction May Prevent Alzheimer's Disease (press ... 

6. [PDF] Five new genetic susceptibility factors identified for Alzheimer's ...
   www.aviesan.fr/en/content/download/.../cp_nature_gen030411.pdf
   File Format: PDF/Adobe Acrobat - Quick View

7. Bapineuzumab - Wikipedia, the free encyclopedia
   en.wikipedia.org/wiki/Bapineuzumab
   "Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease" (Press release). ... 

8. New Acute Antihypertensive CCB, Alzheimer's Disease, and More ...
   www.medscape.com/viewarticle/567233_4

9. Dementia: the Growing Crisis in West Virginia
   www.wvdhhr.org/bph/oehp/hsc/dementia/refer.htm
   70+ items – References · Credits and Acknowledgements. REFERENCES.
   Peck P. Forgetful? Don't assume it's Alzheimer's disease. WebMD Medical ...
   Grossberg GT. Diagnosis and treatment of Alzheimer's disease. J ...
   Gross J. Alzheimer's in the living room: How one family rallies to cope. TheNew ...

10. New Protein Linked to Alzheimer's Disease - Press Release ...
    www.digitaljournal.com/pr/320414
    May 26, 2011 – Manhasset, NY (PRWEB) May 26, 2011 After decades of studying the pathological process that wipes out large volumes of memory, scientists at ...
### IV. US Food and Drug Administration Info on Alzheimer’s Disease

**Drugs@FDA Database**

Original New Drug Approvals (NDAs and BLAs) by Month; last 3 months listed


**September 2011**

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PUR-WASH (NDA # 022305)</td>
<td>PURIFIED WATER</td>
<td>5</td>
<td>S</td>
<td>NIAGARA PHARMA INC</td>
<td>09/01/2011</td>
</tr>
<tr>
<td>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE (NDA # 202171)</td>
<td>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE</td>
<td>4</td>
<td>S</td>
<td>MATRIX LABS LTD</td>
<td>09/08/2011</td>
</tr>
<tr>
<td>LAMIVUDINE; ZIDOVUDINE (NDA # 201151)</td>
<td>LAMIVUDINE; ZIDOVUDINE</td>
<td></td>
<td></td>
<td>CIPLA LIMITED</td>
<td>09/22/2011</td>
</tr>
<tr>
<td>MEMANTINE HYDROCHLORIDE (NDA # 200155)</td>
<td>MEMANTINE HYDROCHLORIDE</td>
<td></td>
<td></td>
<td>TORRENT PHARMS</td>
<td>09/27/2011</td>
</tr>
<tr>
<td>CLOBETASOL PROPIONATE (NDA # 201402)</td>
<td>CLOBETASOL PROPIONATE</td>
<td></td>
<td></td>
<td>PERRIGO ISRAEL</td>
<td>09/27/2011</td>
</tr>
</tbody>
</table>
### August 2011

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Active NDA Chem.</th>
<th>Review Classif-</th>
<th>Company</th>
<th>Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GEMCITABINE</strong></td>
<td>GEMCITABINE</td>
<td>3</td>
<td>S</td>
<td>HOSPIRA INC</td>
</tr>
<tr>
<td>(NDA # 200795)</td>
<td>HYDROCHLORIDE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ROSVASTATIN</strong></td>
<td>ROSUVASTATIN</td>
<td>2</td>
<td>S</td>
<td>WATSON LABS INC</td>
</tr>
<tr>
<td><strong>ZINC</strong> (NDA # 202172)</td>
<td>ZINC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COMPLERA</strong></td>
<td>EMTRICITABINE;</td>
<td>4</td>
<td>P</td>
<td>GILEAD SCIENCES INC</td>
</tr>
<tr>
<td>(NDA # 202123)</td>
<td>RILPIVIRINE;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TENOFOVIR</strong></td>
<td>TENOFOVIR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DISOPROXIL</strong></td>
<td>DISOPROXIL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FUMARATE</strong></td>
<td>FUMARATE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ZELBORAF</strong></td>
<td>VEMURAFENIB</td>
<td>1</td>
<td>P</td>
<td>HOFFMAN N LA ROCHE</td>
</tr>
<tr>
<td>(NDA # 202429)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ADCETRIS</strong></td>
<td>BRENXTIMAB VEOOTIN</td>
<td></td>
<td>SEATTLE GENETICS</td>
<td>08/19/2011</td>
</tr>
<tr>
<td>(BLA # 125388)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ADCETRIS</strong></td>
<td>BRENXTIMAB VEOOTIN</td>
<td></td>
<td>SEATTLE GENETICS</td>
<td>08/19/2011</td>
</tr>
<tr>
<td>(BLA # 125399)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FIRAZYR</strong></td>
<td>ICATIBANT ACETATE</td>
<td>1</td>
<td>P</td>
<td>SHIRE ORPHAN THERAP</td>
</tr>
<tr>
<td>(NDA # 022150)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NUCYNTA ER</strong></td>
<td>TAPENTADOL</td>
<td>3</td>
<td>S</td>
<td>ORTHO MCNEIL JANSSEN</td>
</tr>
<tr>
<td>(NDA # 200533)</td>
<td>HYDROCHLORIDE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>XALKORI</strong></td>
<td>CRIZOTINIB</td>
<td>1</td>
<td>P</td>
<td>PFIZER</td>
</tr>
<tr>
<td>(NDA # 202570)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### July 2011

<table>
<thead>
<tr>
<th>Drug Name and</th>
<th>Active</th>
<th>NDA Chem.</th>
<th>Review Classif-</th>
<th>Company</th>
<th>Approval</th>
</tr>
</thead>
</table>

**Drug Name** and **Active** are the names of the drugs and their respective active ingredients.

**NDA Chem.** and **Review Classif-** refer to the NDA and review classification.

**Company** lists the company responsible for the drug.

**Approval** indicates the date of approval.

_Hitt Medical Writing, LLC © 2011  www.hittmedicalwriting.com_
<table>
<thead>
<tr>
<th>FDA Appl. #</th>
<th>Ingredients</th>
<th>Type</th>
<th>cation</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARCAPTA NEOHALER</td>
<td>INDACATEROL MALEATE</td>
<td>1</td>
<td>S</td>
<td>07/01/2011</td>
</tr>
<tr>
<td>(NDA # 022383)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XARELTO</td>
<td>RIVAROXABAN</td>
<td>1</td>
<td>S</td>
<td>07/01/2011</td>
</tr>
<tr>
<td>(NDA # 022406)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRILINTA</td>
<td>TICAGRELOR</td>
<td>1</td>
<td>S</td>
<td>07/20/2011</td>
</tr>
<tr>
<td>(NDA # 022433)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEPARIN SODIUM</td>
<td>HEPARIN SODIUM</td>
<td>5</td>
<td>S</td>
<td>07/21/2011</td>
</tr>
<tr>
<td>(NDA # 201370)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEPARIN SODIUM</td>
<td>HEPARIN SODIUM</td>
<td>5</td>
<td>S</td>
<td>07/21/2011</td>
</tr>
<tr>
<td>PRESERVATIVE FREE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(NDA # 201370)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPINEPHRINE</td>
<td>EPINEPHRINE</td>
<td></td>
<td></td>
<td>07/29/2011</td>
</tr>
<tr>
<td>(NDA # 201739)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

** Note: Chemical Types: **

<table>
<thead>
<tr>
<th>Number</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>New molecular entity (NME)</td>
</tr>
<tr>
<td>2</td>
<td>New ester, new salt, or other noncovalent derivative</td>
</tr>
<tr>
<td>3</td>
<td>New formulation</td>
</tr>
<tr>
<td>4</td>
<td>New combination</td>
</tr>
<tr>
<td>5</td>
<td>New manufacturer</td>
</tr>
<tr>
<td>6</td>
<td>New indication</td>
</tr>
<tr>
<td>7</td>
<td>Drug already marketed, but without an approved NDA</td>
</tr>
<tr>
<td>8</td>
<td>OTC (over-the-counter) switch</td>
</tr>
</tbody>
</table>

** Review Classification **

<table>
<thead>
<tr>
<th>Letter</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>P</td>
<td>Priority review drug: A drug that appears to represent an advance over available therapy</td>
</tr>
<tr>
<td>S</td>
<td>Standard review drug: A drug that appears to have therapeutic qualities similar to those of an already marketed drug</td>
</tr>
<tr>
<td>O</td>
<td>Orphan drug</td>
</tr>
</tbody>
</table>

2011 Advisory Committee Meetings

http://www.fda.gov/AdvisoryCommittees/Calendar/ucm153468.htm
V. Guidelines in Alzheimer’s Disease

National Guidelines Clearinghouse--Guidelines.gov

www.guidelines.gov; Search criteria = “Alzheimer” all years, sorted by date, first 20 listed

1. Dementia. Diagnosis and treatment. 2011. NGC:008442
   Regione Toscana, Consiglio Sanitario Regionale - State/Local Government Agency [Non-U.S.].
   View all guidelines by the developer(s)

2. GUIDELINE SYNTHESIS Management of Alzheimer’s Disease and Related Dementias

   Institute for Clinical Systems Improvement - Nonprofit Organization. View all guidelines by the developer(s)

   Registered Nurses’ Association of Ontario - Professional Association. View all guidelines by the developer(s)

   Institute for Clinical Systems Improvement - Nonprofit Organization. View all guidelines by the developer(s)

   The North American Menopause Society - Nonprofit Organization. View all guidelines by the developer(s)

   American Occupational Therapy Association, Inc. - Professional Association. View all guidelines by the developer(s)

   American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
   The North American Menopause Society - Nonprofit Organization. View all guidelines by the developer(s)

    American Heart Association - Professional Association; American Stroke Association - Disease Specific Society; Department of Defense - Federal Government Agency [U.S.]; Department of Veterans Affairs - Federal Government Agency [U.S.]; Veterans Health Administration - Federal Government Agency [U.S.]. View all guidelines by the developer(s)

    National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)

12. **Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults**, 2009 Jun. NGC:007517
    American Academy of Sleep Medicine - Professional Association. View all guidelines by the developer(s)

    American Medical Directors Association - Professional Association. View all guidelines by the developer(s)

    Society of Obstetricians and Gynaecologists of Canada - Medical Specialty Society. View all guidelines by the developer(s)

    Canadian Stroke Network - Disease Specific Society; Heart and Stroke Foundation of Canada - Disease Specific Society. View all guidelines by the developer(s)

   Alzheimer’s Association - Disease Specific Society. [View all guidelines by the developer(s)]

   American Academy of Family Physicians - Medical Specialty Society; American College of Physicians - Medical Specialty Society. [View all guidelines by the developer(s)]

19. **Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome,** 2008 Mar. NGC:006417
   National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]. [View all guidelines by the developer(s)]

    Hartford Institute for Geriatric Nursing - Academic Institution. [View all guidelines by the developer(s)]

---

**VI. Conferences and Medical Associations for Alzheimer’s Disease**

---
VII. Key Opinion Leaders in Alzheimer’s Disease

A listing of key opinion leaders (KOLs) in Alzheimer’s Disease who have participated in recent CME activities available online. Where possible, the sponsor information has been listed.

- **Jeffrey L. Cummings, MD**, The Augustus S. Rose Professor of Neurology  Professor of Psychiatry and Biobehavioral Sciences  Director, Mary S. Easton Center for Alzheimer's Disease Research  Director, Deane F. Johnson Center for Neurotherapeutics  David Geffen School of Medicine at UCLA. Dr. Cummings has provided consultation to Abbott, Acadia, Accera, ADAMAS, Astellas, Avanir, Bristol-Myers Squibb, CoMentis, Eisai, Elan, EnVivo, Forest, GlaxoSmithKline, Janssen, Lilly, Lundbeck, Medivation, Merck, Merz, Myriad, Neuren, Neurokos, Novartis, Noven, Orion Pharmaceuticals, Pfizer, Prana, reMYND, Schering Plough, Signum Bioscience, Sonexa, Takeda, Toyama, and Wyeth pharmaceutical companies. He owns stock in ADAMAS, Prana, Sonexa, and Neurokos. He has been a speaker/lecturer for: Eisai, Forest, Janssen, Novartis, Pfizer, Lundbeck, Merz. Dr. Cummings owns the copyright of the Neuropsychiatric Inventory and has provided expert consultation regarding olanzapine and ropinerol.

- **Murray A. Raskind, MD**, Professor and Vice-Chairman  Department of Psychiatry and Behavioral Sciences  University of Washington School of Medicine  Director of the University of Washington Alzheimer's Disease Research Center  Director of Mental Health Service  VA Puget Sound Health Care System  Director of the VA Northwest Network Mental Illness Research, Education and Clinical Center (MIRECC). Consultant and grant/research support: Elan/Janssen.

- **Sandra E. Black, MD, FRCP**, Brill Chair in Neurology  University of Toronto, Sunnybrook Health Sciences Centre  Toronto, Ontario  Canada. Consultant: Pfizer/Wyeth, Janssen-Ortho, BMS  Speaker’s Bureau: Eisai, Pfizer, Novartis, Janssen-Ortho  Grant/Research Support: Pfizer, Roche, Wyeth, Novartis.
VIII. Clinical Trials in Progress in Alzheimer’s Disease

clinicaltrials.gov

Search criteria- Alzheimer’s disease  | Open Studies  | Exclude Unknown  | Phase III, IV

54 of 54 studies listed

| Rank | Study |

Hitt Medical Writing, LLC © 2011  www.hittmedicalwriting.com
1  *Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training*

Condition: Alzheimer's Disease

Interventions: Behavioral: Individualized management of AD including caregiver training; Drug: Memantine

2  *Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease*

Condition: Alzheimer's Disease

Intervention: Drug: donepezil hydrochloride

3  *A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease*

Condition: Alzheimer's Disease

Interventions: Drug: dl-alpha-tocopherol; Drug: Memantine; Drug: Placebo

4  *Donepezil and Memantine in Moderate to Severe Alzheimer's Disease*

Condition: Moderate to Severe Alzheimer's Disease

Interventions:
Drug: Memantine; Drug: Donepezil; Drug: Placebo donepezil; Drug: Placebo memantine

5  *Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease*

Condition: Alzheimer's Disease

Interventions: Behavioral: Standard intervention protocol; Behavioral: Standard intervention protocol + Cognitive training therapy; Behavioral: Standard intervention protocol + Reminiscence therapy; Behavioral: Standard intervention protocol + "Made-to-measure" program

6  *Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type*
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.

Condition: Alzheimer's Disease
Intervention: Drug: Rivastigmine transdermal patch

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: Memantine; Drug: Placebo

Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: Epigallocatechin-Gallate; Drug: Placebo

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer’s Disease Patients

Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine; Other: Exercise training program

Trial of Carvedilol in Alzheimer's Disease

Condition: Alzheimer’s Disease
Interventions: Drug: Carvedilol; Drug: Placebo

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: Huperzine A; Drug: huperzine A; Drug: Placebo

13 **A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease**

Condition: Alzheimer's Disease

Intervention: Drug: Rivastigmine transdermal

14 **Trazodone for Sleep Disorders in Alzheimer's Disease**

Conditions: Sleep; Sleep Disorders; Insomnia; Alzheimer's Disease

Interventions: Drug: Trazodone; Drug: Placebo

15 **A Double-blind, Placebo-controlled, 2-year Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease.**

Conditions: Alzheimer Disease; Dementia, Alzheimer Type

Interventions: Drug: Galantamine; Drug: Placebo

16 **Continued Safety Monitoring of Solanezumab in Alzheimer's Disease**

Condition: Alzheimer's Disease

Intervention: Drug: Solanezumab

17 **Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI**

Condition: Dementia of the Alzheimer Type

Interventions: Behavioral: StaCog, stage specific cognitive intervention; Behavioral: booklet based training

18 **A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's**
Disease

Condition: Alzheimer's Type Dementia

Interventions: Drug: E2020; Drug: Placebo

19  *A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease*

Condition: Alzheimer Disease

Intervention: Dietary Supplement: caprylidene

20  *Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients*

Condition: Alzheimer Disease

Interventions: Drug: bapineuzumab; Drug: placebo

21  *Study Evaluating the Efficacy and Safety of Bapineuzumab in Alzheimer Disease Patients*

Condition: Alzheimer Disease

Interventions: Drug: bapineuzumab; Drug: placebo

22  *Thalidomide for Patients With Mild to Moderate Alzheimer's Disease*

Condition: Alzheimer's Disease

Intervention: Drug: Thalidomide

23  *Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease*

Condition: Alzheimer's Disease

Intervention: Drug: memantine

24  *Citalopram for Agitation in Alzheimer's Disease*
Conditions: Alzheimer's Disease; Agitation

Interventions: Drug: citalopram; Drug: placebo

25  A Long-Term Safety and Tolerability Study of Bapineuzumab in Alzheimer Disease Patients

Condition: Alzheimer Disease

Interventions: Drug: Bapineuzumab 0.5 mg/kg; Drug: Bapineuzumab 1.0 mg/kg

26  A Long-Term Safety and Tolerability Extension Study of Bapineuzumab in Alzheimer Disease Patients

Condition: Alzheimer Disease

Intervention: Drug: Bapineuzumab 0.5 mg/kg

27  A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Condition: Alzheimer's Disease

Intervention: Drug: Rivastigmine

28  Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride - Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease

Condition: Alzheimer's Disease

Intervention: Drug: donepezil hydrochloride

29  A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease

Condition: Alzheimer's Disease

Intervention: Drug: SK-PC-B70M

30  Cilostazol Augmentation Study in Dementia
Condition: Alzheimer's Dementia

Interventions: Drug: Cilostazol; Drug: Placebo

31 **AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)**

Condition: Alzheimer's Disease

Interventions: Drug: caprylic triglyceride; Drug: long-chain triglyceride

32 **Alzheimer's Disease - Input of Vitamin D With mEmantine Assay**

Condition: Alzheimer Disease

Interventions: Drug: Memantine; Drug: Vitamin D; Drug: Vitamin D placebo

33 **Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's**

Conditions: Alzheimer's Disease; Hypertension

Interventions: Drug: Ramipril; Drug: Placebo

34 **Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers**

Condition: Alzheimer's Disease

Interventions: Drug: Experimental 1; Drug: Placebo Comparator

35 **Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)**

Conditions: Alzheimer Disease; Dementia; Dementia, Vascular; Pain

Intervention: Drug: hydrocodone/APAP

36 **Improving Function, Quality of Life, Glycemia in Diabetics With Dementia**

Conditions: Diabetes Mellitus; Alzheimer's Disease; Apathy; Dementia
Interventions: Drug: Methylphenidate;  Drug: Placebo

37  **Hormone and Information Processing Study**

Conditions: Mild Cognitive Disorder;  Alzheimer's Disease

Interventions: Drug: testosterone gel;  Drug: placebo gel

38  **Bupropion for the Treatment of Apathy in Alzheimer's Dementia**

Condition: Apathy in Dementia

Interventions: Drug: Elontril;  Drug: placebo

39  **Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment**

Condition: Mild Cognitive Impairment (MCI)

Interventions: Behavioral: Behavioral Activation (BA);  Behavioral: Supportive Therapy (ST)

40  **Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke**

Conditions: Ischemic Stroke;  Cognitive Decline;  Dementia

Intervention: Behavioral: Motivation and lifestyle intervention

41  **Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients**

Condition: Amnestic Mild Cognitive Impairment

Interventions: Drug: Simvastatin;  Drug: Placebo

42  **Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)**

Condition: Mild Cognitive Impairment

Interventions: Behavioral: caloric restriction;  Behavioral: omega-3 supplementation;  Behavioral: resveratrol supplementation;  Behavioral: Placebo;  Behavioral: 2nd step: intervention + physical / cognitive
training; Behavioral: 2nd step: intervention + control

43 **Caregiver Stress: Interventions to Promote Health and Wellbeing**

Condition: Health Promotion

Interventions: Behavioral: Usual Care; Behavioral: Psycho-education; Behavioral: Psycho-education plus physical exercise

44 **Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder**

Condition: Bipolar Disorder

Interventions: Drug: Galantamine-ER; Drug: Galantamine placebo

45 **Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia**

Conditions: Schizophrenia; Dementia

Intervention: Drug: Huperzine A

46 **Memantine for Post-Operative Pain Control**

Condition: Pain, Post-operative

Interventions: Drug: Memantine; Drug: Placebo

47 **Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia**

Conditions: Parkinson's Disease; Apathy; no Dementia

Interventions: Drug: rivastigmine; Drug: placebo

48 **Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol**

Condition: Subsyndromal Delirium

Interventions: Drug: Haloperidol decanoate; Drug: Placebo
49  **Efficacy and Safety Study of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome**

Condition: Down Syndrome

Interventions: Drug: Memantine;  Drug: Placebo

50  **A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders**

Condition: Autism Spectrum Disorders

Intervention: Drug: Memantine

51  **Aspirin in Reducing Events in the Elderly**

Conditions: Functional Disability;  Dementia;  Heart Disease;  Stroke;  Cancer;  Bleeding

Interventions: Drug: 100 mg enteric-coated aspirin;  Drug: Placebo

52  **Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier**

Condition: Thoracic Aortic Vascular Disease

Intervention: Procedure: Repair of descending thoracic aneurysm and morphine

53  **Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study**

Conditions: Neurocognitive Disturbance;  HIV Infection

Interventions: Drug: Lithium;  Drug: Rivastigmine;  Behavioral: not initiate treatment

54  **Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders**

Condition: Autism

Interventions: Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements;  Drug: Indistinguishable placebo tablets, matching both donepezil and choline
IX. PubMed Search in Alzheimer’s Disease


Search = Alzheimer’s Disease, English only

Randomized Controlled Trials

Results: 16 (published in the last 180 days)


Related citations


Related citations


Related citations


Related citations

5. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment.

Related citations


Related citations


Related citations

8. Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials.

Related citations


Related citations

10. A phase II trial of huperzine A in mild to moderate Alzheimer disease.
PMID: 21502597 [PubMed - indexed for MEDLINE]  
Related citations

11. Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.  
PMID: 21223356 [PubMed - indexed for MEDLINE]  
Related citations

12. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people.  
Kwok T, Lee J, Law CB, Pan PC, Yung CY, Choi KC, Lam LC.  
PMID: 21216507 [PubMed - indexed for MEDLINE]  
Related citations

13. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD.  
Silverman DH, Geist CL, Kenna HA, Williams K, Wroolie T, Powers B, Brooks J, Rasgon NL.  
PMID: 20810219 [PubMed - indexed for MEDLINE]  
Related citations

14. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?  
PMID: 20672243 [PubMed - indexed for MEDLINE]  
Related citations

15. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.  
Guekht AB, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators.  
PMID: 20656516 [PubMed - indexed for MEDLINE]  
Related citations
16. **Improved language performance in Alzheimer disease following brain stimulation.**
   Cotelli M, Calabria M, Manenti R, Rosini S, Zanetti O, Cappa SF, Miniussi C.
   PMID: 20574108 [PubMed - indexed for MEDLINE]
   Related citations

### Reviews

**Results: 22 (published in the last 90 days)**

1. **Molecular chaperones in protein folding and proteostasis.**
   Hartl FU, Bracher A, Hayer-Hartl M.
   PMID: 21776078 [PubMed - indexed for MEDLINE]
   Related citations

2. **Fighting neurodegeneration with rapamycin: mechanistic insights.**
   Bové J, Martínez-Vicente M, Vila M.
   PMID: 21772323 [PubMed - indexed for MEDLINE]
   Related citations

3. **Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.**
   PMID: 21764118 [PubMed - indexed for MEDLINE]
   Related citations

4. **Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration.**
   Saxena S, Caroni P.
   PMID: 21745636 [PubMed - indexed for MEDLINE]
   Related citations

5. **AMP-activated protein kinase: a potential player in Alzheimer's disease.**
   Salminen A, Kaarniranta K, Haapasalo A, Soininen H, Hiltunen M.
   Cheung ZH, Ip NY.
   PMID: 21599666 [PubMed - indexed for MEDLINE]
   Related citations

7. Alpha T-catenin (CTNNA3): a gene in the hand is worth two in the nest.
   Smith JD, Meehan MH, Crean J, McCann A.
   PMID: 21598020 [PubMed - indexed for MEDLINE]
   Related citations

   Veerhuis R, Nielsen HM, Tenner AJ.
   PMID: 21546088 [PubMed - indexed for MEDLINE]
   Related citations

9. Drug targets for cognitive enhancement in neuropsychiatric disorders.
   Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG.
   PMID: 21463652 [PubMed - indexed for MEDLINE]
   Related citations

    Dumas JA, Newhouse PA.
    PMID: 21382398 [PubMed - indexed for MEDLINE]
    Related citations

11. Attention-modulating effects of cognitive enhancers.
    Levin ED, Bushnell PJ, Rezvani AH.
12. **Alzheimer's disease and age-related memory decline (preclinical).**
   Terry AV Jr, Callahan PM, Hall B, Webster SJ.
   PMID: 21315756 [PubMed - indexed for MEDLINE]

13. **Acetylcholine: future research and perspectives.**
   Van der Zee EA, Platt B, Riedel G.
   PMID: 21295616 [PubMed - indexed for MEDLINE]

14. **The cholinergic system in aging and neuronal degeneration.**
   Schliebs R, Arendt T.
   PMID: 21145918 [PubMed - indexed for MEDLINE]

15. **Acetylcholine and memory: a long, complex and chaotic but still living relationship.**
   Micheau J, Marighetto A.
   PMID: 21130809 [PubMed - indexed for MEDLINE]

16. **The cholinergic system, circadian rhythmicity, and time memory.**
   Hut RA, Van der Zee EA.
   PMID: 21115064 [PubMed - indexed for MEDLINE]

17. **The redox basis of epigenetic modifications: from mechanisms to functional consequences.**
   Cyr AR, Domann FE.
   PMID: 20919933 [PubMed - in process]

Related citations
18. **Hydrogen sulfide: neurophysiology and neuropathology.**
   Hu LF, Lu M, Hon Wong PT, Bian JS.
   PMID: 20812864 [PubMed - in process]
   Related citations

19. **The cholinergic system, nerve growth factor and the cytoskeleton.**
   Niewiadomska G, Mietelska-Porowska A, Mazurkiewicz M.
   PMID: 20170684 [PubMed - indexed for MEDLINE]
   Related citations

20. **The cerebrovascular role of the cholinergic neural system in Alzheimer's disease.**
   Van Beek AH, Claassen JA.
   PMID: 20060023 [PubMed - indexed for MEDLINE]
   Related citations

21. **The cholinergic system and Parkinson disease.**
   Bohnen NI, Albin RL.
   PMID: 20060022 [PubMed - indexed for MEDLINE]
   Related citations

22. **The history of the cholinergic hypothesis.**
   Contestabile A.
   PMID: 20060018 [PubMed - indexed for MEDLINE]
   Related citations

**Editorials**

**Results: 17 (published in the last 90 days)**

1. **Defining and describing the pre-dementia stages of familial Alzheimer's disease.**
   Ryan NS, Rossor MN.
   PMID: 21952009 [PubMed - as supplied by publisher]
   Related citations

2. **Primary care practitioners on the front line of Alzheimer's disease care.**
Oustric S, Rouge-Bugat ME, Vellas B.  
PMID: 21856241 [PubMed - in process]

Related citations

3. **Amyloid imaging in prodromal Alzheimer's disease.**  
Ossenkoppele R, van Berckel BN, Prins ND.  
PMID: 21936965 [PubMed - as supplied by publisher]

Related citations

4. **Loss of activated CaMKII at the synapse underlies Alzheimer's disease memory loss.**  
Ly PT, Song W.  
PMID: 21899538 [PubMed - as supplied by publisher]

Related citations

5. **Neuropsychiatric symptoms in Alzheimer's disease.**  
PMID: 21889116 [PubMed - in process]

Related citations

6. **Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease.**  
Lista S, Emanuele E.  

Related citations

7. **New diagnostic criteria for Alzheimer's disease.**  
Zetterberg H.  

Related citations

8. **New drugs for Alzheimer's disease in Japan.**  
Takeda M, Tanaka T, Okochi M.
9. **Tau Protein and Alzheimer’s Disease.**
   Maccioni RB.
   PMID: 21827396 [PubMed - as supplied by publisher]

10. **Consequences of antipsychotic medications for the dementia patient.**
    Devanand DP, Schultz SK.
    PMID: 21813491 [PubMed - indexed for MEDLINE]

11. **Nanomedicine in the European Commission policy for nanotechnology.**
    Gabellieri C, Frima H.
    PMID: 21802394 [PubMed - in process]

12. **Alzheimer’s disease.**
    Brody H.
    PMID: 21760574 [PubMed - indexed for MEDLINE]

13. **Risk factors for Alzheimer disease: aging beyond age?**
    Dartigues JF, Féart C.
    PMID: 21753168 [PubMed - indexed for MEDLINE]

14. **Nutrition and Alzheimer’s disease: is there any connection?**
    Ramassamy C, Belkacémi A.
    PMID: 21679155 [PubMed - in process]
15. **Bionanotechnologies for treatment and diagnosis of Alzheimer's disease.**
   Moghimi SM.  
   PMID: 21616169 [PubMed - in process]  
   Related citations

16. **The search of new biomarkers to identify Alzheimer's disease: an editorial comment to T. Vanmierlo et al. 'The plant sterol brassicasterol and additional CFS biomarker in Alzheimer's Disease' (1).**
   Lobo A, Quintanilla MA.  
   PMID: 21564039 [PubMed - in process]  
   Related citations

17. **Cognitive enhancers for the treatment of neuropsychiatric disorders: clinical and preclinical investigations.**
   Kantak KM, Hofmann SG.  
   PMID: 21316387 [PubMed - indexed for MEDLINE]  
   Related citations